Cancer gene therapy market seen reaching $8.9 billion by 2030

The cancer gene therapy market is projected to nearly double from $4.21 billion in 2025 to $8.9 billion by 2030, according to The Business Research Company. Growth is being driven by rising cancer cases, expanding cell and gene therapy investment, and broader use of precision oncology approaches.

Why it matters: - Cancer gene therapy is moving from a niche treatment approach toward a larger role in oncology as demand grows for more targeted and less toxic options. - The market’s projected climb to $8.9 billion by 2030 signals continued investment in genetic and cell-based cancer treatments. - Rising cancer incidence is widening the patient base that could benefit from these therapies.

What happened: - The Business Research Company said the global cancer gene therapy market will grow from $4.21 billion in 2025 to $4.9 billion in 2026. - The market is projected to reach $8.9 billion by 2030, reflecting a 16.1% CAGR over the forecast period. - The report was published Nov. 6, 2026, and covers market trends across North America, South America, Western Europe, Eastern Europe, Asia-Pacific, South East Asia, the Middle East and Africa. - The company also offered a free sample of the report and a full market report.

The details: - The report links recent growth to progress in molecular oncology research, more gene therapy clinical trials, higher biopharmaceutical R&D spending, regulatory approvals of early gene therapies and better vector manufacturing. - Future growth is expected to come from stronger demand for personalized cancer therapies, more cell and gene therapy production investment, next-generation viral vectors and wider use of combination oncology treatments. - Cancer gene therapy works by introducing or altering genes in a patient’s cells to slow cancer growth or strengthen the immune response against tumors. - The approach is positioned as a more targeted alternative to traditional cancer therapies. - The report says the market is also being supported by rising adoption of CAR-T and TCR therapies and biomarker-guided treatment strategies. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

Between the lines: - The forecast suggests cancer gene therapy is becoming less experimental and more commercial as manufacturing, approvals and clinical adoption mature. - The emphasis on combination therapies and biomarker-guided treatment points to a market increasingly shaped by precision medicine rather than one-size-fits-all oncology. - The report’s regional split suggests the next wave of growth may come from both established U.S. and European markets and faster-building Asia-Pacific infrastructure.

What's next: - The market is expected to keep expanding through 2030 as more therapies move through development and commercialization. - Investment in viral vectors, production capacity and personalized treatment platforms should remain key watchpoints. - Broader adoption of CAR-T, TCR and combination approaches could further widen the addressable market.